Eidogen-Sertanty Licenses Discovery Informatics Software and Databases to Cephalon
News Jan 06, 2006
Eidogen-Sertanty, Inc. has announced that Cephalon, Inc. will access Eidogen-Sertanty's Kinase Knowledgebase (KKB™), Target Informatics Platform™ (TIP™), and EVE™ Comparative Visualization software.
Scientists at Cephalon will use the proprietary software to support small molecule drug discovery projects in their neurology and oncology therapeutic programs.
"We are pleased to provide Cephalon with broad access to several of our discovery informatics products," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
"We're confident that our kinase informatics and structural informatics solutions will help the experienced research team at Cephalon accelerate their lead discovery efforts."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE